Article

Bexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease

2026-08-04

Abstract excerpt

Bruton’s tyrosine kinase (BTK) transduces B-cell receptor (BCR), Toll-like receptor (TLR), and Fc receptor (FcR) signaling, and overactivation of these pathways drives B-cell malignancies and antibody-mediated autoimmune disease. Small molecule inhibitors block the enzymatic functions of BTK, but this inhibition is undermined by resistance mutations, several of which abolish BTK’s kinase activity yet promote oncog...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b7c5a80b-915e-549a-be8f-0e2336418351
DOI: 10.64898/2026.08.01.740538

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Bexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated DiseaseDOI 10.64898/2026.08.01.740538Read

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.Semantic proximity Read

New Means and Challenges in the Targeting of BTK.Semantic proximity Read

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and functionSemantic proximity Read

Integrated proteomic screening reveals design principles of CRBN molecular glue degradersSemantic proximity Read

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine KinaseSemantic proximity Read

The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapySemantic proximity Read

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogenySemantic proximity Read

Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.Semantic proximity Read

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read